Antiangiogenic Approaches to Age-Related Macular Degeneration in the Future

被引：25

作者：

Do, Diana V. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA

来源：

OPHTHALMOLOGY | 2009年 / 116卷 / 10期

关键词：

COMPLEMENT FACTOR-H; RANIBIZUMAB;

D O I：

10.1016/j.ophtha.2009.06.049

中图分类号：

R77 [眼科学];

学科分类号：

100212 [眼科学];

摘要：

Neovascular age-related macular degeneration (AMD) is a complex disease that likely involves multiple angiogenic agents that contribute to the development of choroidal neovascularization (CNV). Although inhibition of vascular endothelial growth factor with ranibizumab has demonstrated efficacy and safety in the treatment of neovascular AMD, novel treatments targeting different mechanisms that play a role in CNV development currently are being investigated. Data from these clinical trials will increase our knowledge of the pathogenesis of AMD and likely provide additions to the treatment armamentarium for improving vision and quality of life in patients with AMD. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the CME frontmatter. Ophthalmology 2009;116:S24-S26 (C) 2009 by the American Academy of Ophthalmology.

引用

页码：S24 / S26

页数：3

共 14 条

[1]

Barouch Fina C., 2004, International Ophthalmology Clinics, V44, P23, DOI 10.1097/00004397-200404430-00005

[2]

Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab [J].

Brantley, Milam A., Jr. ;

Fang, Amy M. ;

King, Jennifer M. ;

Tewari, Asheesh ;

Kymes, Steven M. ;

Shiels, Alan .

OPHTHALMOLOGY, 2007, 114 (12) :2168-2173

[3]

Ranibizumab versus verteporfin for neovascular age-related macular degeneration [J].

Brown, David M. ;

Kaiser, Peter K. ;

Michels, Mark ;

Soubrane, Gisele ;

Heier, Jeffrey S. ;

Kim, Robert Y. ;

Sy, Judy P. ;

Schneider, Susan .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1432-1444

[4]

*CLINICALTRIALS, 2009, PHAS 1 SAF TOL PHARM

[5]

*CLINICALTRIALS, EFF SAF VERT PHOT TH

[6]

*CLINICALTRIALS, RED FLUENC VIS ANT D

[7]

Complement factor H polymorphism and age-related macular degeneration [J].

Edwards, AO ;

Ritter, R ;

Abel, KJ ;

Manning, A ;

Panhuysen, C ;

Farrer, LA .

SCIENCE, 2005, 308 (5720) :421-424

[8]

Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564

[9]

Gehrs, Karen M. ;

Anderson, Don H. ;

Johnson, Lincoln V. ;

Hageman, Gregory S. .

ANNALS OF MEDICINE, 2006, 38 (07) :450-471

[10]

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss - AREDS Report No. 8 [J].

Kassoff, A ;

Kassoff, J ;

Buehler, J ;

Eglow, M ;

Kaufman, F ;

Mehu, M ;

Kieval, S ;

Mairs, M ;

Graig, B ;

Quattrocchi, A ;

Jones, D ;

Locatelli, J ;

Ruby, A ;

Capone, A ;

Garretson, B ;

Hassan, T ;

Trese, MT ;

Williams, GA ;

Regan, V ;

Manatrey, P ;

Streasick, P ;

Szydlowski, L ;

McIver, F ;

Bridges, C ;

Stanley, C ;

Cumming, K ;

Lewis, B ;

Zajechowski, M ;

Margherio, RR ;

Cox, MS ;

Camille, J ;

Falk, R ;

Siedlak, P ;

Neubert, C ;

Klein, ML ;

Stout, JT ;

O'Malley, A ;

Lauer, AK ;

Robertson, JE ;

Wilson, DJ ;

Beardsley, C ;

Anderson, H ;

Wallace, P ;

Smith, G ;

Howard, S ;

Dreyer, RF ;

Ma, C ;

Chenoweth, RG ;

Zilis, JD ;

Johnson, M .

ARCHIVES OF OPHTHALMOLOGY, 2001, 119 (10) :1417-1436

← 1 2 →